Visakorpi T - Search Results

1

AR and ERG drive the expression of prostate cancer specific long noncoding RNAs.

Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J, Tammela TLJ, Kivinummi K, Latonen L, Nykter M, Visakorpi T. Kohvakka A, et al. Among authors: visakorpi t. Oncogene. 2020 Jul;39(30):5241-5251. doi: 10.1038/s41388-020-1365-6. Epub 2020 Jun 17. Oncogene. 2020. PMID: 32555329

2

Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy.

Koivisto P, Hyytinen E, Palmberg C, Tammela T, Visakorpi T, Isola J, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Am J Pathol. 1995 Dec;147(6):1608-14. Am J Pathol. 1995. PMID: 7495286 Free PMC article.

3

Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.

Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Visakorpi T, et al. Cancer Res. 1995 Jan 15;55(2):342-7. Cancer Res. 1995. PMID: 7529134

4

In vivo amplification of the androgen receptor gene and progression of human prostate cancer.

Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. Visakorpi T, et al. Nat Genet. 1995 Apr;9(4):401-6. doi: 10.1038/ng0495-401. Nat Genet. 1995. PMID: 7795646

5

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.

Koivisto P, Visakorpi T, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Scand J Clin Lab Invest Suppl. 1996;226:57-63. Scand J Clin Lab Invest Suppl. 1996. PMID: 8981668 Review.

6

Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer.

Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Cancer Res. 1997 Jan 15;57(2):314-9. Cancer Res. 1997. PMID: 9000575

7

Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade.

Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1997;31(2):216-9. doi: 10.1159/000474453. Eur Urol. 1997. PMID: 9076469

8

Androgen receptor gene and hormonal therapy failure of prostate cancer.

Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Koivisto P, et al. Among authors: visakorpi t. Am J Pathol. 1998 Jan;152(1):1-9. Am J Pathol. 1998. PMID: 9422516 Free PMC article. Review.

9

Molecular biology of progression of prostate cancer.

Nupponen N, Visakorpi T. Nupponen N, et al. Among authors: visakorpi t. Eur Urol. 1999;35(5-6):351-4. doi: 10.1159/000019907. Eur Urol. 1999. PMID: 10325488 Review.

10

PSA decline is an independent prognostic marker in hormonally treated prostate cancer.

Palmberg C, Koivisto P, Visakorpi T, Tammela TL. Palmberg C, et al. Among authors: visakorpi t. Eur Urol. 1999 Sep;36(3):191-6. doi: 10.1159/000067996. Eur Urol. 1999. PMID: 10450001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters